Principal Investigator
Macarena De La Fuente
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20180606
National Clinical Trials Identifier
NCT03684109
Clinical Trial Summary
MRI-based sequences can provide non-invasive quantification of intratumoral
2-hydroxyglutarate (2HG) distribution and tumor cellularity in human gliomas and help guide
the development of novel glioma therapies.
Phase
N/A
Funding Agency/Sponsor
Institutional
Disease
Neurological Cancer
Enrollment Eligibility
Inclusion Criteria:
- Adults (≥18 year old)
- Subjects with suspected or confirmed gliomas and who will have a medically indicated
biopsy or resection of his/her brain lesion.
Exclusion Criteria:
- Adults unable to consent
- Individuals who are not yet adults (infants, children, teenagers)
- Pregnant women
- Patients unable to have MRI done